The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2017 | The evolution of CAR T-cell therapy
Steven Rosen, MD, from the City of Hope, Duarte, CA, discusses the evolution of CAR T-cell therapy at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. CAR T-cells have so far shown very promising results, even in relapsed and refractory settings. This therapy is still in its infancy, and therefore there will be continuous improvement in terms of the toxicity profile, and how it is administered. Initially, it has been carried out in specialist centres, however, there is hope that it will evolve into a more common and widespread treatment.
